DZ2665A1 - Conjugués utiles pour le traitement du cancer de la prostate. - Google Patents

Conjugués utiles pour le traitement du cancer de la prostate.

Info

Publication number
DZ2665A1
DZ2665A1 DZ980275A DZ980275A DZ2665A1 DZ 2665 A1 DZ2665 A1 DZ 2665A1 DZ 980275 A DZ980275 A DZ 980275A DZ 980275 A DZ980275 A DZ 980275A DZ 2665 A1 DZ2665 A1 DZ 2665A1
Authority
DZ
Algeria
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Application number
DZ980275A
Other languages
English (en)
French (fr)
Inventor
Stephen F Brady
Feng Dong-Mei
Victor M Garsky
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DZ2665A1 publication Critical patent/DZ2665A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DZ980275A 1997-12-02 1998-11-30 Conjugués utiles pour le traitement du cancer de la prostate. DZ2665A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DZ2665A1 true DZ2665A1 (fr) 2003-03-22

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980275A DZ2665A1 (fr) 1997-12-02 1998-11-30 Conjugués utiles pour le traitement du cancer de la prostate.

Country Status (26)

Country Link
US (2) US20060148718A1 (pl)
EP (1) EP1036093A1 (pl)
JP (1) JP2001525337A (pl)
KR (1) KR100580137B1 (pl)
CN (1) CN1181092C (pl)
AR (1) AR016427A1 (pl)
AU (1) AU744652B2 (pl)
BG (1) BG65486B1 (pl)
BR (1) BR9815116A (pl)
CA (1) CA2311615A1 (pl)
DZ (1) DZ2665A1 (pl)
EA (1) EA002745B1 (pl)
EE (1) EE200000333A (pl)
HR (1) HRP20000367A2 (pl)
HU (1) HUP0100350A3 (pl)
ID (1) ID24735A (pl)
IL (1) IL136167A0 (pl)
IS (1) IS5502A (pl)
NO (1) NO20002804L (pl)
NZ (1) NZ504615A (pl)
PE (1) PE20000009A1 (pl)
PL (1) PL197006B1 (pl)
SK (1) SK8282000A3 (pl)
TR (1) TR200002260T2 (pl)
TW (1) TW577897B (pl)
WO (1) WO1999028345A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773420B2 (en) * 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN104955484B (zh) * 2012-08-15 2019-01-15 文森医学公司 用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法
AU2013341711A1 (en) * 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP2992531B1 (en) 2013-04-30 2019-06-19 Hewlett-Packard Enterprise Development LP Memory access rate
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
WO2022136586A1 (en) 2020-12-22 2022-06-30 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
DE3484691D1 (de) * 1983-04-29 1991-07-18 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
JP2001501601A (ja) * 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
BG65486B1 (bg) 2008-09-30
CN1284086A (zh) 2001-02-14
US20070021350A1 (en) 2007-01-25
HRP20000367A2 (en) 2000-12-31
EE200000333A (et) 2001-08-15
WO1999028345A1 (en) 1999-06-10
JP2001525337A (ja) 2001-12-11
EP1036093A1 (en) 2000-09-20
CA2311615A1 (en) 1999-06-10
AR016427A1 (es) 2001-07-04
AU1612399A (en) 1999-06-16
EA200000603A1 (ru) 2000-12-25
KR20010032687A (ko) 2001-04-25
AU744652B2 (en) 2002-02-28
EA002745B1 (ru) 2002-08-29
NZ504615A (en) 2003-05-30
IS5502A (is) 2000-05-19
PE20000009A1 (es) 2000-01-27
TW577897B (en) 2004-03-01
NO20002804L (no) 2000-07-21
PL197006B1 (pl) 2008-02-29
HUP0100350A2 (hu) 2001-08-28
BG104563A (en) 2001-04-30
PL340768A1 (en) 2001-02-26
NO20002804D0 (no) 2000-05-31
BR9815116A (pt) 2000-10-10
IL136167A0 (en) 2001-05-20
HUP0100350A3 (en) 2001-09-28
CN1181092C (zh) 2004-12-22
SK8282000A3 (en) 2000-11-07
KR100580137B1 (ko) 2006-05-16
ID24735A (id) 2000-08-03
US20060148718A1 (en) 2006-07-06
TR200002260T2 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
DZ2333A1 (fr) Conjugues utiles au traitement du cancer de la prostate
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
EP1104423A4 (en) ANHYDRIDE-MODIFIED CANTHARIDINE ANALOGS SUITABLE FOR CANCER THERAPY
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DK0972024T4 (da) Tumorsuppressor designeret TS10Q23.3
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
FI960658L (fi) Uudet bis-naftalimidit syövän hoitamiseksi
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
PT1043025E (pt) Tratamento de carcinoma da celula renal
ZA200203166B (en) Treatment of cancer.
MA26830A1 (fr) Pyrroles substituees utilisees en tant qu'agents anti-proliferants pour le traitement du cancer
EP1157694A4 (en) REMEDIES OF THE ERECTIONAL DISORDER
FR2785545B3 (fr) Calecon pour le traitement topique de la cellulite
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
EP1019529A4 (en) METHOD FOR TREATING CANCER
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
FR2686391B3 (fr) Ensemble de robinet.